What tranexamic acid is

Tranexamic acid (INCI: TRANEXAMIC ACID) is a synthetic derivative of lysine with the formula C8H15NO2 and a molecular weight near 157 Da — a very simple small molecule. It is not a "botanical brightening extract" but a strictly single chemical entity, which makes its purchasing and QC profile very different from botanical brighteners: purity, impurity profiles and related substances can be quantified precisely by HPLC, and batch-to-batch consistency is far better than for extracts. It travels under several names in Chinese — tranexamic acid, tranexamic acid, tranexamic acid — so INCI and CAS are the only reliable identifiers; always verify against those two.

Its origin matters, because that is exactly where the risk comes from: tranexamic acid was developed and long used orally as an antifibrinolytic haemostatic drug; only later was topical application found helpful for the look of pigmentation, and it migrated into skin care. That drug-to-cosmetic history carries one consequence: supplier literature and published work lean heavily on oral and clinical contexts, and lifting those conclusions straight into cosmetic copy is the most common way this ingredient gets you into trouble. The cosmetic side must keep every statement at the level of appearance and evenness of tone, and must not imply any pharmaceutical use in consumer communication.

Its physico-chemical profile is friendly, which is why it is so widely used: a white crystalline powder, freely soluble in water and glycerin, practically insoluble in oils and most organic solvents; as an amino-acid-type molecule it is reasonably heat-stable and can go into the water phase before emulsification, though stability falls in strong acid and very low pH gradually hydrolyses it. There is also a processing detail that must be written into the formulation brief up front: as an amphoteric amino-acid-type ingredient, tranexamic acid markedly interferes with carbomer thickening, dropping viscosity or preventing gel formation altogether. This is not solved by adding more carbomer — the thickener must be chosen at the system-design stage, typically switching to xanthan gum, hydroxyethyl cellulose, sodium polyacrylate families or a compounded emulsified system. If this is not settled at project kick-off, sampling has a high probability of bouncing back with "we cannot get the viscosity right".

Ingredient fact box

How it works, plainly

The hypothesis can be split into three layers, from molecule to appearance: switching something off at protein level, sending fewer signals, and producing a little less pigment in visible terms. State this at the outset: this section covers mechanistic hypotheses and literature at the cosmetic application level — it is not a medical explanation and carries no efficacy promise.

• Layer one: interaction with the plasmin system. This is the most recognisable part. Its classic identity is as an antifibrinolytic agent, meaning it acts on the plasmin system. The published hypothesis runs that keratinocytes, under stress such as UV, release plasminogen activator and thereby generate plasmin; this cascade drives the release of prostaglandins and arachidonic-acid-derived mediators downstream, which in turn issues more "work signals" to melanocytes. Tranexamic acid is thought to intervene in that chain and help reduce the generation of such signals.
• Layer two: less agitation upstream. Following the layer above — if prostaglandin-type mediators agitate melanocyte activity less, melanocytes receive weaker stimulation. The industry often summarises this as "reducing the excessive response to external stress", and it is why tranexamic acid also appears in gentle brightening formulas: unlike acids, which work by exfoliation, or high-dose vitamin C, which brings acidity and a strong redox environment, it is comparatively mild on the barrier and therefore better suited to the thin, low-tolerance eye area.
• Layer three: what shows up visually. The upper layers appear as less severe unevenness of tone and a smaller contrast between dark patches and surrounding skin — what consumers call looking more even and brighter. Be honest: this is an appearance-level description, not "spots disappearing", and certainly not a biochemical assertion such as "inhibits melanin production". You may write "helps improve the look of dullness and uneven tone around the eyes"; you must not write "removes spots", "fades spots" or "inhibits melanin" — in China those fall inside the scope of spot-fading and whitening special cosmetics.
• An honest note on evidence strength. There is a fair body of published work on tranexamic acid for facial melasma and post-inflammatory pigmentation; verify it yourself on PubMed with "tranexamic acid melasma" and "tranexamic acid pigmentation". But note that concentrations, dosage forms, durations and populations differ widely across those studies, and most are not eye-area specific. Presenting facial findings as eye-area findings is not rigorous, and no single study may be written up as proof of efficacy.
• How it divides work with other brighteners. Tranexamic acid is not well suited to being sold as the single brightening active; its proper place is the "pigmentation signalling" link inside a complex. Complementary actives include alpha-arbutin, acting at tyrosinase (see our alpha-arbutin eye care guide at ingredient.html?s=alpha-arbutin), niacinamide, leaning towards melanosome transfer to keratinocytes, and 3-o-ethyl ascorbic acid, working by reduction and antioxidant routes. Combining them covers different steps — it is not a case of "more actives equals more effect".

A blunt note for sourcing: if your brief reads "dullness around the eyes", tranexamic acid is a cost-controllable, formulation-friendly choice with a clear evidence trail. If the expectation is fast spot removal, it will disappoint — its only honest story is gradual, cumulative evenness of tone. More importantly: given its haemostatic origin, supplier material often carries oral dosage, indication and discontinuation language, and none of that should be copied onto your product page.

Which formats fit tranexamic acid best?

Use level and formulation notes (verify by bench trial)

Common reference level: tranexamic acid commonly sits at ≈2%–5% in skin-care products; but periorbital skin is thinner and less tolerant, so actual dosing usually starts at the lower end and is raised only against irritation and stability data. Two points deserve emphasis. First, tranexamic acid is a compound rather than an extract, so the use level is the actual content of that compound — there is no dual "extract versus assay" basis, which ironically makes purchasing documents simpler than for botanicals. Second, oral dosages in the literature and topical use levels are two entirely different systems and must never be cross-quoted. The actual level is set on the bench by format, compatibility, target-market rules and stability data, converted against the assay on the supplier COA.

• Thickener choice is constraint #1. As an amphoteric amino-acid-type ingredient, tranexamic acid markedly weakens carbomer thickening, showing up as viscosity that never builds, thinning or phase separation. Move to xanthan gum, hydroxyethyl cellulose, sodium polyacrylate families or a compounded system at design stage, and run three to four parallel candidate thickeners during sampling.
• Crystallisation is constraint #2. At high use levels, low water content or under cold storage, tranexamic acid may crystallise out, most visible in clear gels and serums. Improve solubility by tuning the polyol ratio (glycerin / butylene glycol / pentylene glycol), and observe samples under cold storage (0–5 °C) and freeze–thaw cycling.
• pH window. Keep it at 5.5–7.0. Strong acid accelerates hydrolysis, so do not build a single system with high-dose low-pH acids such as AHAs or high-level salicylic acid; if a combination is needed, separate the format or the usage step and verify with retained samples.
• Manage the astringent feel. Mid to high levels bring a slight dry, tightening sensation, more noticeable in an area that shows dryness lines as readily as the eye contours. Balance it conventionally with sodium hyaluronate, glycerin, panthenol and lightweight lipids to avoid the counterproductive "tight enough to show lines" result.
• Processing. It can be added and fully dissolved during the heated water phase (it is relatively heat-stable), with emulsification or thickening following complete dissolution. Confirm there are no visible crystals before charging, or undissolved particles may end up in the finished goods.
• Stability protocol. 40 °C for 3 months, freeze–thaw and cold-storage crystallisation checks, with tranexamic acid retention (HPLC), pH drift, viscosity change and visible crystallisation as release criteria.
• Label and claim review. Before launch, a regulatory adviser must confirm the usable boundary of "brightening / evening / radiance" copy per market — especially for China, where spot-fading and whitening is a special cosmetic category requiring registration, not something an ordinary cosmetic may claim on its own.

The figures above are common reference levels for eye care formulas; the actual use level is set by the formulation engineer based on dosage form, compatibility and target-market rules. Permitted use conditions, limits and labelling requirements differ by market — complete a compliance review for each destination before shipment. All descriptions here are general cosmetic applications and appearance or skin-feel statements, not medical advice or efficacy guarantees.

Compliance and market notes (verify per target market)

• China: first verify the listing status and historical maximum use level of tranexamic acid (tranexamic acid) in the Inventory of Existing Cosmetic Ingredients in China (2021 edition) (per the latest NMPA announcement). The critical point: spot-fading and whitening products are special cosmetics in China, requiring registration and an approval number before manufacture or import; ordinary cosmetics may not claim spot-fading or whitening. The Chinese wording recommended here is therefore limited to appearance descriptions such as "helps improve the look of periorbital dullness and uneven tone" — "祛斑", "淡斑", "美白" and "抑制黑色素" must not appear on labels or pages of products without that registration.
• Japan: tranexamic acid has a long history of use in Japanese quasi-drugs, and the claim framework there does not follow China's special-registration logic. On a quasi-drug pathway, the active, its level and the permitted wording must be checked line by line against Japan's then-current quasi-drug system; if entering as a cosmetic, no quasi-drug efficacy wording may be carried over. Confirm the latest rules with a regulatory adviser for the target market.
• EU (EC) No 1223/2009: declare the ingredient accurately in the CPNP notification, PIF and CPSR, and complete the safety assessment; claims must meet the (EU) No 655/2013 common criteria. Note that tolerance for "whitening / spot-fading" claims differs sharply from China — in several EU member states the word "whitening" may be read as implying a physiological change, so prefer appearance wording such as "helps even the look of skin tone".
• US MoCRA (2022): facility registration, product listing, safety substantiation, adverse-event reporting and record-keeping apply, with labelling under the FD&C Act and relevant 21 CFR provisions. Cosmetic ingredients and finished products generally do not undergo pre-market approval — never write "FDA approved". A further caution specific to this ingredient: because tranexamic acid has an established drug identity, any copy implying therapeutic use risks being read as a drug claim, reclassifying the product — the single highest-priority risk in this article.
• Claim red lines (all markets): never use medical, biochemical or special-function wording such as "removes spots", "fades spots", "whitening", "treats melasma", "inhibits melanin production", "anticoagulant" or "stops bleeding". On the Chinese site use appearance wording such as "helps improve the look of periorbital dullness and uneven tone", "helps the periorbital complexion look more even" and "boosts a translucent look".
• Recommended action: at project kick-off, give your regulatory adviser five items — ingredient, use level and basis, dosage form, target country and proposed claim copy — for one upfront review. Also require legal sign-off line by line on any copy containing a brightening claim, since that single word is the easiest route on this site into special-cosmetic or drug-claim territory.

Ingredient pairings

• Tranexamic acid + niacinamide (2%–5%): the most common pair in brightening formulas. The two cover different steps of the pigmentation pathway — one leaning upstream on signalling, the other on transfer — both are water-soluble and water-phase carried, so processing compatibility is good. Watch overall tolerance when both sit high; start at the lower end around the eyes.
• Tranexamic acid + alpha-arbutin (1%–2%): a classic pairing covering both "signalling" and tyrosinase steps. For the compliance framing on arbutin, see our alpha-arbutin eye care guide (ingredient.html?s=alpha-arbutin); the same claim boundaries apply to the combination.
• Tranexamic acid + sodium hyaluronate + panthenol: offsets the astringency tranexamic acid can bring and lays down a hydration base for the main story. This pairing is about tolerance rather than extra strength, which matters especially in an area that shows dryness lines so readily.
• Tranexamic acid + ectoin + ceramides: a barrier-first combination for tolerance-sensitive or flush-prone users on an evenness line; for the repair pathway see our ectoin eye care guide (ingredient.html?s=ectoin).
• Tranexamic acid + caffeine: covers a combined dullness and puffiness brief, addressing two different conversations and suiting a morning-oriented all-round eye cream.
• Use with care: combining with low-pH high-dose acid systems (AHAs / salicylic acid) accelerates hydrolysis, so separate the format or the usage step; there is a marked viscosity conflict with carbomer thickening, to be ruled out at thickener selection; assess solubility and crystallisation alongside a high electrolyte load; and avoid stacking many brighteners at high levels, since cumulative irritation and cost both become unmanageable — cap the formula at two to three headline actives.

Formulation pairing cards

FAQ

Image briefs